Historical Valuation
Milestone Pharmaceuticals Inc (MIST) is now in the Fair zone, suggesting that its current forward PS ratio of 5.09 is considered Fairly compared with the five-year average of -3.02. The fair price of Milestone Pharmaceuticals Inc (MIST) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：2.12
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Milestone Pharmaceuticals Inc (MIST) has a current Price-to-Book (P/B) ratio of 10.16. Compared to its 3-year average P/B ratio of 2.28 , the current P/B ratio is approximately 346.18% higher. Relative to its 5-year average P/B ratio of 2.33, the current P/B ratio is about 336.68% higher. Milestone Pharmaceuticals Inc (MIST) has a Forward Free Cash Flow (FCF) yield of approximately -20.72%. Compared to its 3-year average FCF yield of -35.26%, the current FCF yield is approximately -41.23% lower. Relative to its 5-year average FCF yield of -27.75% , the current FCF yield is about -25.32% lower.
P/B
Median3y
2.28
Median5y
2.33
FCF Yield
Median3y
-35.26
Median5y
-27.75
Competitors Valuation Multiple
AI Analysis for MIST
The average P/S ratio for MIST competitors is 1.82, providing a benchmark for relative valuation. Milestone Pharmaceuticals Inc Corp (MIST.O) exhibits a P/S ratio of 5.09, which is 178.75% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MIST
1Y
3Y
5Y
Market capitalization of MIST increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MIST in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MIST currently overvalued or undervalued?
Milestone Pharmaceuticals Inc (MIST) is now in the Fair zone, suggesting that its current forward PS ratio of 5.09 is considered Fairly compared with the five-year average of -3.02. The fair price of Milestone Pharmaceuticals Inc (MIST) is between to according to relative valuation methord.
What is Milestone Pharmaceuticals Inc (MIST) fair value?
MIST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Milestone Pharmaceuticals Inc (MIST) is between to according to relative valuation methord.
How does MIST's valuation metrics compare to the industry average?
The average P/S ratio for MIST's competitors is 1.82, providing a benchmark for relative valuation. Milestone Pharmaceuticals Inc Corp (MIST) exhibits a P/S ratio of 5.09, which is 178.75% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Milestone Pharmaceuticals Inc (MIST) as of Jan 09 2026?
As of Jan 09 2026, Milestone Pharmaceuticals Inc (MIST) has a P/B ratio of 10.16. This indicates that the market values MIST at 10.16 times its book value.
What is the current FCF Yield for Milestone Pharmaceuticals Inc (MIST) as of Jan 09 2026?
As of Jan 09 2026, Milestone Pharmaceuticals Inc (MIST) has a FCF Yield of -20.72%. This means that for every dollar of Milestone Pharmaceuticals Inc’s market capitalization, the company generates -20.72 cents in free cash flow.
What is the current Forward P/E ratio for Milestone Pharmaceuticals Inc (MIST) as of Jan 09 2026?
As of Jan 09 2026, Milestone Pharmaceuticals Inc (MIST) has a Forward P/E ratio of -4.21. This means the market is willing to pay $-4.21 for every dollar of Milestone Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Milestone Pharmaceuticals Inc (MIST) as of Jan 09 2026?
As of Jan 09 2026, Milestone Pharmaceuticals Inc (MIST) has a Forward P/S ratio of 5.09. This means the market is valuing MIST at $5.09 for every dollar of expected revenue over the next 12 months.